论文部分内容阅读
目的:探讨乳腺癌组织中组蛋白去乙酰化酶-1(histone deacetylase 1,HDAC-1)的表达意义及其与临床病理特征之间存在的相关性。方法:应用免疫组织化学Envision二步法检测120例乳腺癌组织和对照组20例乳腺增生症乳腺组织中HDAC-1蛋白的表达,分析其与临床特征,以及常规检测指标雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(human epidermalgrowth factor receptor-2,HER-2)之间的关系。结果:120例乳腺浸润性导管癌中,HDAC-1高表达43例(35.83%),对照组20例乳腺增生病变中HDAC-1低表达或不表达,两者之间表达差异有统计学意义。乳腺癌中HDAC-1高表达与年龄、临床分期、HER-2表达均有显著相关性(P<0.01),即与患者年龄>50岁组(49.50%)和临床分期为Ⅲ～Ⅳ期组(64.28%)及HER-2(55.26%)的表达呈正相关;与肿瘤的大小、组织学分级、淋巴结转移的有无、以及癌组织间及癌旁组织中有无淋巴细胞的浸润无相关(P>0.05),与ER(33.89%)、PR(39.28%)的表达无相关(P>0.05)。结论:HDAC-1在乳腺癌和良性增生性病变诊断及鉴别诊断中有参考意义;HDAC-1蛋白在乳腺癌的发生发展中起重要作用;HDAC-1抑制剂有望成为乳腺癌治疗的新靶向药物。
Objective: To investigate the expression of histone deacetylase 1 (HDAC-1) in breast cancer and its relationship with clinicopathological features. Methods: The expression of HDAC-1 protein in 120 cases of breast cancer and 20 cases of breast hyperplasia was detected by Envision immunohistochemistry. The expression of HDAC-1 protein in 120 cases of breast cancer and control group were analyzed. The clinical characteristics and the expression of estrogen receptor ), Progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2). Results: HDAC-1 was highly expressed in 43 cases (35.83%) in 120 cases of invasive ductal carcinoma of the breast. The expression of HDAC-1 was low or not expressed in 20 cases of hyperplasia of mammary gland. The difference between the two groups was statistically significant . The expression of HDAC-1 in breast cancer was significantly correlated with age, clinical stage and HER-2 expression (P <0.01), which was related to the age of patients> 50 years old (49.50%) and clinical stage Ⅲ ~ Ⅳ (64.28%) and HER-2 (55.26%). There was no correlation between tumor size and histological grade, lymph node metastasis and infiltration of lymphocytes in adjacent tissues P> 0.05). There was no correlation between ER (33.89%) and PR (39.28%) (P> 0.05). Conclusion: HDAC-1 is useful in the diagnosis and differential diagnosis of breast cancer and benign proliferative lesions. HDAC-1 protein plays an important role in the development of breast cancer. HDAC-1 inhibitor is expected to become a new target for the treatment of breast cancer To medicine.